INTRODUCTION:AZD6244 (ARRY-142886) is a potent, selective MEK inhibitor. This study aimed to evaluate the efficacy and safety of AZD6244 versus pemetrexed as second- or third-line treatment in patients with advanced non-small cell lung cancer (NSCLC). METHODS: In this randomized phase II study, patients received either 100 mg oral AZD6244 free-base suspension twice daily or 500 mg/m(2) intravenous pemetrexed once every 3 weeks after pretreatment with a corticosteroid, folic acid, and vitamin B12. The primary end point of the study was the disease progression event count. RESULTS:Eighty-four patients were randomized. Disease progression events were experienced by 28 (70%) and 26 (59%) patients in the AZD6244 and pemetrexed groups, respectively. Median progression-free survival was not statistically significantly different between the AZD6244 and pemetrexed groups (67 versus 90 days, respectively; hazard ratio 1.08, two-sided 80% confidence interval = 0.75-1.54; p = 0.79). Two patients in the AZD6244 group had a best response to treatment of partial response. In the pemetrexed group, one patient achieved a complete response and one patient a partial response. Dermatitis acneiform, diarrhea, nausea, and vomiting were the most frequently reported adverse events with AZD6244, compared with fatigue, anemia, nausea, anorexia, and dermatitis acneiform with pemetrexed. CONCLUSIONS: Oral AZD6244 showed clinical activity as second- or third-line therapy for patients with advanced NSCLC. In an unselected NSCLC population, there is no suggestion that AZD6244 monotherapy offers any advantage over standard treatment with pemetrexed. Based on preclinical data and recent clinical observations, further development of AZD6244 in NSCLC should focus on BRAF or RAS mutation-positive patients and/or AZD6244-based combination regimens.
RCT Entities:
INTRODUCTION:AZD6244 (ARRY-142886) is a potent, selective MEK inhibitor. This study aimed to evaluate the efficacy and safety of AZD6244 versus pemetrexed as second- or third-line treatment in patients with advanced non-small cell lung cancer (NSCLC). METHODS: In this randomized phase II study, patients received either 100 mg oral AZD6244 free-base suspension twice daily or 500 mg/m(2) intravenous pemetrexed once every 3 weeks after pretreatment with a corticosteroid, folic acid, and vitamin B12. The primary end point of the study was the disease progression event count. RESULTS: Eighty-four patients were randomized. Disease progression events were experienced by 28 (70%) and 26 (59%) patients in the AZD6244 and pemetrexed groups, respectively. Median progression-free survival was not statistically significantly different between the AZD6244 and pemetrexed groups (67 versus 90 days, respectively; hazard ratio 1.08, two-sided 80% confidence interval = 0.75-1.54; p = 0.79). Two patients in the AZD6244 group had a best response to treatment of partial response. In the pemetrexed group, one patient achieved a complete response and one patient a partial response. Dermatitis acneiform, diarrhea, nausea, and vomiting were the most frequently reported adverse events with AZD6244, compared with fatigue, anemia, nausea, anorexia, and dermatitis acneiform with pemetrexed. CONCLUSIONS: Oral AZD6244 showed clinical activity as second- or third-line therapy for patients with advanced NSCLC. In an unselected NSCLC population, there is no suggestion that AZD6244 monotherapy offers any advantage over standard treatment with pemetrexed. Based on preclinical data and recent clinical observations, further development of AZD6244 in NSCLC should focus on BRAF or RAS mutation-positive patients and/or AZD6244-based combination regimens.
Authors: Bert H O'Neil; Laura W Goff; John Sae Wook Kauh; Jonathan R Strosberg; Tanios S Bekaii-Saab; Ruey-Min Lee; Aslamuzzaman Kazi; Dominic T Moore; Maria Learoyd; Richard M Lush; Said M Sebti; Daniel M Sullivan Journal: J Clin Oncol Date: 2011-04-25 Impact factor: 44.544
Authors: Rafael B Blasco; Sarah Francoz; David Santamaría; Marta Cañamero; Pierre Dubus; Jean Charron; Manuela Baccarini; Mariano Barbacid Journal: Cancer Cell Date: 2011-04-21 Impact factor: 31.743
Authors: Osamu Takahashi; Ritsuko Komaki; Paul D Smith; Juliane M Jürgensmeier; Anderson Ryan; B Nebiyou Bekele; Ignacio I Wistuba; Jörg J Jacoby; Maria V Korshunova; Anna Biernacka; Baruch Erez; Keiko Hosho; Roy S Herbst; Michael S O'Reilly Journal: Clin Cancer Res Date: 2012-01-24 Impact factor: 12.531
Authors: Nitin Jain; Emily Curran; Neil M Iyengar; Ernesto Diaz-Flores; Rangesh Kunnavakkam; Leslie Popplewell; Mark H Kirschbaum; Theodore Karrison; Harry P Erba; Margaret Green; Xavier Poire; Greg Koval; Kevin Shannon; Poluru L Reddy; Loren Joseph; Ehab L Atallah; Philip Dy; Sachdev P Thomas; Scott E Smith; L Austin Doyle; Walter M Stadler; Richard A Larson; Wendy Stock; Olatoyosi Odenike Journal: Clin Cancer Res Date: 2013-10-31 Impact factor: 12.531
Authors: Savita Bhalla; Andrew M Evens; Bojie Dai; Sheila Prachand; Leo I Gordon; Ronald B Gartenhaus Journal: Blood Date: 2011-05-31 Impact factor: 22.113
Authors: Zhao Chen; Katherine Cheng; Zandra Walton; Yuchuan Wang; Hiromichi Ebi; Takeshi Shimamura; Yan Liu; Tanya Tupper; Jing Ouyang; Jie Li; Peng Gao; Michele S Woo; Chunxiao Xu; Masahiko Yanagita; Abigail Altabef; Shumei Wang; Charles Lee; Yuji Nakada; Christopher G Peña; Yanping Sun; Yoko Franchetti; Catherine Yao; Amy Saur; Michael D Cameron; Mizuki Nishino; D Neil Hayes; Matthew D Wilkerson; Patrick J Roberts; Carrie B Lee; Nabeel Bardeesy; Mohit Butaney; Lucian R Chirieac; Daniel B Costa; David Jackman; Norman E Sharpless; Diego H Castrillon; George D Demetri; Pasi A Jänne; Pier Paolo Pandolfi; Lewis C Cantley; Andrew L Kung; Jeffrey A Engelman; Kwok-Kin Wong Journal: Nature Date: 2012-03-18 Impact factor: 49.962
Authors: Mathewos Tessema; Christin M Yingling; Amanda M Snider; Kieu Do; Daniel E Juri; Maria A Picchi; Xiequn Zhang; Yushi Liu; Shuguang Leng; Carmen S Tellez; Steven A Belinsky Journal: J Thorac Oncol Date: 2014-06 Impact factor: 15.609